EQS-News: HeartBeat.bio collaborates with Boehringer Ingelheim to investigate cardiac organoids for the development of new treatments for people with heart diseases
Retrieved on:
Wednesday, October 5, 2022
Molecular Devices, EQS, Time, Drug, Cardioid, Drug development, 3D, Degenerative disease, Research, Regeneration, Vienna, Institute, Technology, AWS, Company, Drug discovery, Austrian Research Promotion Agency, IMBA, AG, Heart failure, Boehringer Ingelheim, CEO, FFG, Vienna Biocenter, Safety, News, Clinical trial, Cell, Institute of Molecular Biotechnology, Seed (programming), Solution, Myocardial infarction, Security (finance), Pharmaceutical industry
The collaboration aims to accelerate development of new therapy options and achieve better outcomes for people with heart diseases.
Key Points:
- The collaboration aims to accelerate development of new therapy options and achieve better outcomes for people with heart diseases.
- Boehringer Ingelheim will work with the scientists from HeartBeat.bio to further advance the companys platform using selected reference compounds from Boehringer Ingelheims research and development programs.
- [1] Existing cardiac safety screening models, such as cardiomyocytes, are limited in predictability as they are not able to sufficiently recapitulate human heart physiology.
- HeartBeat.bios heart organoids are stem-cell derived 3D cell culture systems, which mimic the human heart physiology in a totally new way.